COMP <GO>
NPK vs TMO // RSI-14 & 200D SMA MOMENTUM
National Presto Industries Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: NPK 5
— TMO 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: TMO
LAST: $151.77 (+0.66%) • MKT CAP: $1.08B
rsi-technicals
54.9
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
rsi-technicals
62.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NPK VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NPK | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 16.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.10% | 9.30% | -1.20 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.1x | 30.4x | -13.30 | NPK | /valuation <GO> |
| Free Cash Flow Yield | -3.34% | 2.40% | -5.74 | TMO | /fcf-yield <GO> |
| Operating Margin | 8.00% | 17.40% | -9.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 6.60% | 15.10% | -8.50 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 29.70% | 3.90% | +25.80 | NPK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 0.24% | +0.42 | NPK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.22 | 4.50 | +4.72 | NPK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 54.9 | 62.9 | -8.00 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | 36.3x | -8.80 | NPK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.08B | $262.22B | -$261.13B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NPK REV | TMO REV | NPK GROSS % | TMO GROSS % | NPK FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $503.5M | $44.56B | 16.0% | — | -$36.2M | $6.29B |
| FY 2024 | $388.2M | $42.88B | 20.2% | — | -$61.0M | $7.27B |
| FY 2023 | $340.9M | $42.86B | — | — | $45.4M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NPK // BETA —
TMO // BETA 0.94